NGNE - NASDAQ
Neurogene Inc.
$26.22
+0.31%Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
At a Glance
Live SnapshotNeurogene Inc. Management Team
Dr. Julie Jordan M.D.
Chief Medical Officer
Compensation
$651,036
Dr. Stuart Cobb Ph.D.
Chief Scientific Officer
Compensation
$478,807
Dr. Rachel L. McMinn Ph.D.
Founder, Executive Chair & Chief Executive Officer
Compensation
$929,410
Ms. Christine Mikail Cvijic J.D.
President & Chief Financial Officer
Compensation
$746,750
Mr. Arvind Sreedharan
Senior Vice President of Business Operations
Dr. Effie Albanis M.D.
Senior Vice President of Early Clinical & Translational Research
Dr. Andrew E. Mulberg CPI, FAAP, M.D.
Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control
Mr. Ricardo Jimenez
Senior Vice President of Technical Operations
Ms. Donna M. Cochener-Metcalfe J.D.
Senior Vice President, General Counsel & Corporate Secretary
Neurogene Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.23M and sold $494K worth of NGNE shares, resulting in $735K of net buying activity.
3 Months
0
0.00
15.5K
373.24K
-373K
-$373K
3-6 Months
0
0.00
4.8K
120.53K
-121K
-$121K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
60.3K
1.23M
0
0.00
+1.2M
+$1.23M
Top Buyers
Baffi Robert
Director
$246K
Woods Robert Keith
Director
$246K
Palekar Rohan
Director
$246K
Freedland Cory S.
Director
$246K
Noonberg Sarah B.
Director
$246K
Top Sellers
Cvijic Christine Mikail
Director, Officer: President And Cfo
$320K
Cobb Stuart
Officer: Chief Scientific Officer
$81K
Mcminn Rachel
Director, Officer: Chief Executive Officer
$74K
Jordan Julie
Officer: Chief Medical Officer
$18K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $735K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
NGNE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | June 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | April 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | April 26, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | March 31, 2022 | May 12, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 31, 2021 | May 13, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 24, 2020 | May 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | October 02, 2019 | November 12, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 26, 2018 | May 07, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 28, 2017 | May 08, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.